Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.38 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.37 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.37 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TPMT | P51580 | 1/20 | 0.36 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.35 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.35 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.35 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14931958 | 0.84 | HSD17B10 (0.51) | HSD17B10LCKFYNPOLBTDP1 | |
| SCHEMBL26625432 | 0.81 | KEAP1 (0.47) | HSD17B10KEAP1NFE2L2LCKFYN | |
| SCHEMBL24291812 | 0.80 | HSD17B10 (0.47) | HSD17B10LCKFYNPOLBTDP1 | |
| SCHEMBL29656639 | 0.80 | HSD17B10 (0.47) | HSD17B10LCKFYNPOLBTDP1 | |
| SCHEMBL2768497 | 0.80 | KEAP1 (0.64) | HSD17B10KEAP1NFE2L2LCKFYN | |
| SCHEMBL30827313 | 0.78 | KEAP1 (0.60) | HSD17B10KEAP1NFE2L2LCKFYN | |
| SCHEMBL28304423 | 0.78 | KEAP1 (0.60) | HSD17B10KEAP1NFE2L2LCKFYN | |
| SCHEMBL3450933 | 0.77 | KEAP1 (0.50) | HSD17B10KEAP1NFE2L2LCKFYN | |
| SCHEMBL23779674 | 0.75 | HSD17B10 (0.40) | HSD17B10LCKFYNPOLBTDP1 | |
| SCHEMBL29657217 | 0.75 | POLB (0.49) | HSD17B10KEAP1NFE2L2LCKFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043420-A1 | 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2024-02-08 | — | — | US | disclosed |
| EP-4225741-A1 | 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | Enliven Therapeutics, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| CN-116438182-A | 7-azaindole compounds for inhibiting BCR-ABL tyrosine kinase | 活力疗法公司 | 2023-07-14 | — | — | CN | disclosed |
| WO-2022076973-A1 | 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN THERAPEUTICS, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | AARDEA BIOSCIENCES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | AARDEA BIOSCIENCES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | AARDEA BIOSCIENCES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| EP-2231665-A2 | NOVEL COMPOSITIONS AND METHODS OF USE | Ardea Biosciences, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009089263-A2 | NOVEL COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES INC. (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | TYMP, SAMHD1, PNP | HSD17B10 617/4885KEAP1 3810/4885NFE2L2 4628/4885 |
| US-20240043420-A1 | 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ABL1, ABL2, BCR | HSD17B10 4391/4885KEAP1 971/4885NFE2L2 1642/4885 |
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | TYMP, SAMHD1, PNP | HSD17B10 617/4885KEAP1 3810/4885NFE2L2 4628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.